Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Sci Rep
; 13(1): 4648, 2023 03 21.
Article
em En
| MEDLINE
| ID: mdl-36944687
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Influenza Humana
/
Vacinas contra COVID-19
/
COVID-19
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article